Cargando…
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options
OBJECTIVES: To review the available systemic treatments for women with recurrent ovarian cancer. METHODS: A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews. RESULTS: We discuss the efficacy and toxicity outcom...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585576/ https://www.ncbi.nlm.nih.gov/pubmed/23459506 http://dx.doi.org/10.2147/OTT.S30238 |
_version_ | 1782261184782663680 |
---|---|
author | Elit, Laurie Hirte, Hal |
author_facet | Elit, Laurie Hirte, Hal |
author_sort | Elit, Laurie |
collection | PubMed |
description | OBJECTIVES: To review the available systemic treatments for women with recurrent ovarian cancer. METHODS: A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews. RESULTS: We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer. Clearly, platinum-based combination systemic therapy shows a prolonged progression-free interval compared with single-agent chemotherapy with a low toxicity profile. No clear superior management strategy exists for platinum-resistant/refractory disease. Novel targeted antiangiogenic agents (eg, bevacizumab), angiopoeitin inhibitors (eg, AMG 386), and poly ADP ribose polymerase inhibitors (eg, olaparib) are reviewed. CONCLUSION: Although combination platinum-based chemotherapy has shown benefits for women with platinum-sensitive recurrent ovarian cancer, the optimal treatment strategy for those with platinum-resistant or platinum-refractory disease is not clear. Molecular and genetic targeted therapies may provide opportunities for those women with tumor profiles that show sensitivity for specific agents. |
format | Online Article Text |
id | pubmed-3585576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-35855762013-03-04 Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options Elit, Laurie Hirte, Hal Onco Targets Ther Review OBJECTIVES: To review the available systemic treatments for women with recurrent ovarian cancer. METHODS: A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews. RESULTS: We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer. Clearly, platinum-based combination systemic therapy shows a prolonged progression-free interval compared with single-agent chemotherapy with a low toxicity profile. No clear superior management strategy exists for platinum-resistant/refractory disease. Novel targeted antiangiogenic agents (eg, bevacizumab), angiopoeitin inhibitors (eg, AMG 386), and poly ADP ribose polymerase inhibitors (eg, olaparib) are reviewed. CONCLUSION: Although combination platinum-based chemotherapy has shown benefits for women with platinum-sensitive recurrent ovarian cancer, the optimal treatment strategy for those with platinum-resistant or platinum-refractory disease is not clear. Molecular and genetic targeted therapies may provide opportunities for those women with tumor profiles that show sensitivity for specific agents. Dove Medical Press 2013-02-26 /pmc/articles/PMC3585576/ /pubmed/23459506 http://dx.doi.org/10.2147/OTT.S30238 Text en © 2013 Elit and Hirte, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Elit, Laurie Hirte, Hal Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options |
title | Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options |
title_full | Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options |
title_fullStr | Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options |
title_full_unstemmed | Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options |
title_short | Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options |
title_sort | palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585576/ https://www.ncbi.nlm.nih.gov/pubmed/23459506 http://dx.doi.org/10.2147/OTT.S30238 |
work_keys_str_mv | AT elitlaurie palliativesystemictherapyforwomenwithrecurrentepithelialovariancancercurrentoptions AT hirtehal palliativesystemictherapyforwomenwithrecurrentepithelialovariancancercurrentoptions |